ArriVent Biopharma presents proof-of-concept data from Phase 1b FURTHER trial

ArriVent BioPharma (AVBP) presented positive final proof-of-concept data from the randomized global Phase 1b FURTHER trial for first-line firmonertinib monotherapy in patients with non-small cell lung cancer , NSCLC, harboring EGFR PACC mutations at the IASCLC 2025 annual World Conference on Lung Cancer, WCLC, in Barcelona, Spain. Key Highlights of Longer-term Final Analysis Data for Firmonertinib Monotherapy: Maintained Clinically Meaningful PFS and Durable Responses: 16.0 months mPFS with firmonertinib once daily 240 mg by BICR, with majority of patients remaining on study; 14.6 months median duration of response with firmonertinib 240 mg by BICR; 68.2% and 43.5% confirmed ORR by BICR at 240 mg and 160 mg, respectively; Confirmed responses at first tumor assessment in the majority of patients; 42.9% CNS confirmed ORR and 35.7% CNS confirmed CRs in CNS evaluable disease front-line patients by BICR. Safety Profile Continues to be Consistent with No New Safety Signals: Generally well-tolerated and manageable safety profile maintained over longer treatment duration; Most frequent treatment-related adverse events include diarrhea, hepatic enzyme elevation, rash, stomatitis, and dry skin. Rapidly Decreased or Cleared PACC ctDNA in Frontline Patients: 82% and 79% ctDNA clearance in frontline PACC patients treated with firmonertinib at 240 mg and 160 mg, respectively, in patients with detectable PACC ctDNA at baseline; Consistent decreases in ctDNA across different PACC mutations were observed including in patients with frequent, less frequent and compound mutations.